Most people are familiar with cancer stages 1 through 4, but stage 0 cancer is less widely known. Cancer staging describes how far the disease has progressed, and for many years, the TNM Classification of Malignant Tumors has been used worldwide to categorize solid tumors based on size, lymph node involvement, and metastasis.
The TNM system traditionally relied on visible symptoms that often appear after cancer cells have spread. Advances in medical imaging and screening now allow doctors to detect abnormal cells before they become invasive. This has led to the identification of carcinoma in situ—also called stage 0 cancer—which means “cancer in place.”
Stage 0 cancer is the earliest form of the disease and is noninvasive, meaning it has not spread beyond its original location. Survival rates for this stage approach 100% in many cases.
“It’s a relatively new concept in cancer staging,” said Chad Ritch, M.D., M.B.A., F.A.C.S., a surgeon at Sylvester Comprehensive Cancer Center and professor at the Miller School of Medicine’s Desai Sethi Urology Institute. “It’s an early cancer, like a superficial cancer.”
Dr. Ritch noted that while stage 0 cancers are highly treatable and often curable, they are rare because abnormal cells are usually too small to be detected by internal scans such as MRI or ultrasound. Precancerous cells on external tissues like skin or cervix are more easily found.
Carcinoma in situ commonly appears in organs such as the bladder, lungs, skin, breasts, and cervix. Early detection generally leads to effective treatment.
In stage 0 bladder cancer, abnormal cells remain confined to the bladder lining without invading deeper layers. There are two subtypes: Stage 0a (tumors located where urine collects) and Stage 0is (abnormal cells spread across the lining without forming a tumor). Dr. Ritch explained that Stage 0is is more concerning due to its aggressive nature and higher risk of becoming invasive.
Treatment varies by subtype: Stage 0a typically involves minimally invasive tumor removal followed by chemotherapy delivered into the bladder; Stage 0is is treated with BCG immunotherapy inside the bladder and may include chemotherapy if needed. The ten-year survival rate exceeds 90%, but recurrence remains common.
“The issue is recurrence, so surveillance is very important,” Dr. Ritch said. “About 30% to 40% of cases return because cancer cells can remain in the bladder lining.”
Stage 0 lung cancer accounts for less than three percent of lung cases and is usually discovered incidentally during unrelated imaging tests, according to Estelamari Rodriguez, M.D., M.P.H., a breast and thoracic oncologist at Sylvester Comprehensive Cancer Center.
“It is more frequently found in women, never-smokers, and people of Asian descent,” Dr. Rodriguez said. “It’s often associated with mutations in the EGFR gene.” These genetic changes lead to uncontrolled cell growth typical of some non-small cell lung cancers.
Early-stage lesions appear as ground-glass opacities on scans and show a lepidic growth pattern under microscopic examination without high-risk features like pleural invasion.
Surgical resection—removal of part or all of an organ—is standard treatment for stage 0 lung cancer; radiation or chemotherapy are rarely required.
“If the disease is diffuse or unresectable, we monitor patients closely,” Dr. Rodriguez said. “I have patients we’ve followed for years with no major changes.”
Among all stage 0 cancers, breast ductal carcinoma in situ (DCIS) is most common—accounting for about one-fifth of new breast cancer diagnoses each year—thanks largely to regular mammogram screenings using advanced digital imaging technology.
“We now have an opportunity to catch it before it spreads, which improves the breast cancer survival rate to about 100%,” said Elisa Krill-Jackson, M.D., a breast medical oncologist at Sylvester Comprehensive Cancer Center.
Treatment depends on hormone receptor status and tumor size but often includes lumpectomy surgery; radiation therapy may follow to reduce recurrence risk. If hormone receptors test positive for estrogen or progesterone sensitivity, anti-estrogen therapy might be recommended; active surveillance could be suitable for low-risk patients instead of immediate intervention.
Despite favorable outcomes at this early stage—and excellent prognosis—the diagnosis still causes anxiety among patients concerned about their future health risks or financial costs related to ongoing monitoring procedures required after initial treatment ends.
“Patients are fearful that this means their life is at risk when—in fact—this has been detected before the abnormal cells have escaped the walls of the breast duct and therefore have no opportunity to spread,” Dr. Krill-Jackson said.“You have to help them understand that—of all potential diagnoses—this is a best-case scenario.”
Dr. Ritch also highlighted concerns over cost: “There’s stress from both diagnosis itself plus ongoing surveillance—but bladder cancer remains one of medicine’s most expensive conditions requiring continued care even after successful initial treatments.”
With accurate diagnosis followed by appropriate therapy tailored specifically toward individual needs based upon specific type(s) present within each patient case history profile(s), experts agree there should be essentially no risk posed from life-threatening metastatic disease developing later down line if caught early enough:
“It’s caught early—it’s small—it hasn’t had chance yet spreading elsewhere—and it remains very treatable overall,” Dr.Krill-Jackson concluded.
